Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study.

Improvements were observed across all PROMIS-29 domains, most notably pain, fatigue, physical function, satisfaction with social participation, and depression; improvements in these domains were nominally significant for both guselkumab treatment groups compared with placebo at Week 24.

also in 7,732 other papers

This difference between the SF-36 and the PROMIS-29 may help explain the observation that in the DISCOVER-1 study, improvements in the SF-36 MCS did not reach statistical significance for guselkumab versus placebo at Week 24 [ 21 ], but improvements in PROMIS-29 T-scores for depression were nominally significant.

also in 111,027 other papers